Kura Oncology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Troy Edward Wilson
- Full Time Employees
- 192
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12730 High Bluff Drive San Diego CA United States of America 92130
- IPO Date
- Sep 16, 2015
- CIK
- 0001422143
- Website
- kuraoncology.com
- Similar Companies
- Business
- Kura Oncology, Inc. (KURA) develops precision medicines targeting cancer signaling pathways for blood cancers and solid tumors. The company focuses on small molecule drug candidates, including its lead menin inhibitor ziftomenib for NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) in monotherapy and combinations with therapies such as venetoclax/azacitidine, cytarabine/daunorubicin (7+3), gilteritinib, FLAG-IDA, and low-dose cytarabine (LDAC); next-generation farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) in monotherapy and combinations with cabozantinib or adagrasib for KRAS G12C-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC); tipifarnib, an oral FTI, in combination with alpelisib for head and neck squamous cell carcinoma (HNSCC) with HRAS mutations; and a next-generation menin inhibitor in research. Kura Oncology, founded in 2014, maintains headquarters in San Diego, California, with additional operations in Boston, Massachusetts, and conducts global clinical trials targeting genetically defined patient populations in oncology. In November 2024, the company enters a global strategic collaboration with Kyowa Kirin Co., Ltd. to co-develop and commercialize ziftomenib for AML and other hematologic malignancies, featuring a $330 million upfront payment, up to $1.161 billion in milestones including $420 million near-term, 50/50 U.S. profit-sharing, tiered double-digit royalties, and Kyowa Kirin's opt-in for solid tumors like gastrointestinal stromal tumors (GIST); Kura advances ziftomenib combinations to registration-enabling trials such as KOMET-017 for frontline AML in the second half of 2025, initiates Phase 1 KOMET-015 with imatinib for advanced GIST, and plans data presentations on FTIs at the European Society for Medical Oncology Congress in October 2025.
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript
Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Kura Oncology Q1 Earnings Call Highlights
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Kura Oncology Reports First Quarter 2026 Financial Results
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML